Genomic and Clinicopathological Characterization of CRLF2-Rearranged Mixed Phenotype Acute Leukemia
Lina Han
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorRuifang Zheng
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorFranklin Fuda
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorMiguel D. Cantu
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorPrasad Koduru
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorJesse M. Jaso
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorOlga Weinberg
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorSharon Germans
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorMingyi Chen
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorJing Xu
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorCorresponding Author
Weina Chen
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Correspondence: Weina Chen ([email protected])
Search for more papers by this authorLina Han
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorRuifang Zheng
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorFranklin Fuda
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorMiguel D. Cantu
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorPrasad Koduru
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorJesse M. Jaso
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorOlga Weinberg
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorSharon Germans
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorMingyi Chen
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorJing Xu
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for more papers by this authorCorresponding Author
Weina Chen
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Correspondence: Weina Chen ([email protected])
Search for more papers by this authorFunding: The authors received no specific funding for this work.
ABSTRACT
Rearrangements of cytokine receptor-like factor 2 gene (CRLF2) are present in ∼50% of B-lymphoblastic leukemia/lymphoma (B-ALL) with BCR::ABL1-like features. Herein, we report three patients with CRLF2-rearranged mixed phenotype acute leukemia (MPAL). All three cases were B/myeloid MPAL in young patients harboring P2RY8::CRLF2 or IGH::CRLF2 with additional genomic alterations in signaling (JAK and RAS) and cell cycle (CDKN2A/B) pathways, a genomic profile similar to that in BCR::ABL1-like B-ALL. Our study is the first case series to demonstrate clinicopathological and genomic features of this underrecognized entity. We recommend upfront genetic/molecular testing to timely diagnose and further characterize MPAL with BCR::ABL1-like features.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| pbc31507-sup-0001-SuppMat.pdf906.4 KB | Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1D. A. Arber, A. Orazi, R. P. Hasserjian, et al., “International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data,” Blood 140, no. 11 (2022): 1200–1228.
- 2J. D. Khoury, E. Solary, O. Abla, et al., “The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms,” Leukemia 36, no. 7 (2022): 1703–1719.
- 3O. K. Weinberg, D. A. Arber, H. Dohner, et al., “The International Consensus Classification of Acute Leukemias of Ambiguous Lineage,” Blood 141, no. 18 (2023): 2275–2277.
- 4G. Cario, V. Leoni, V. Conter, A. Baruchel, M. Schrappe, and A. Biondi, “BCR-ABL1-Like Acute Lymphoblastic Leukemia in Childhood and Targeted Therapy,” Haematologica 105, no. 9 (2020): 2200–2204.
- 5S. K. Tasian, M. L. Loh, and S. P. Hunger, “Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia,” Blood 130, no. 19 (2017): 2064–2072.
- 6A. Yoda, Y. Yoda, S. Chiaretti, et al., “Functional Screening Identifies CRLF2 in Precursor B-Cell Acute Lymphoblastic Leukemia,” PNAS 107, no. 1 (2010): 252–257.
- 7S. K. Tasian and M. L. Loh, “Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia,” Critical Reviews in Oncogenesis 16, no. 1–2 (2011): 13–24.
- 8I. Iacobucci and K. G. Roberts, “Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia,” Genes (Basel) 12, no. 5 (2021): 687.
- 9T. H. Tran and S. K. Tasian, “How I Treat Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults,” Blood (2024):2023023153, https://doi.org/10.1182/blood.2023023153.
10.1182/blood.2023023153 Google Scholar
- 10I. Tanasi, I. Ba, N. Sirvent, et al., “Efficacy of Tyrosine Kinase Inhibitors in Ph-Like Acute Lymphoblastic Leukemia Harboring ABL-class Rearrangements,” Blood 134, no. 16 (2019): 1351–1355.
- 11R. Zheng, F. Fuda, J. R. Gagan, et al., “Genomic Heterogeneity Within B/T Mixed Phenotype Acute Leukemia in a Context of an Immunophenotype,” Leukemia Research Reports 21 (2024): 100410.
- 12S. M. Choi, J. K. Frederiksen, C. W. Ross, D. L. Bixby, and L. Shao, “Philadelphia Chromosome-Like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation,” American Journal of Clinical Pathology 148, no. 6 (2017): 523–528.
- 13A. S. Duffield, C. G. Mullighan, and M. J. Borowitz, “International Consensus Classification of Acute Lymphoblastic Leukemia/Lymphoma,” Virchows Archiv 482, no. 1 (2023): 11–26.
- 14O. K. Weinberg, J. Dennis, H. Zia, et al., “Adult Mixed Phenotype Acute Leukemia (MPAL): B/Myeloid MPAL(isoMPO) Is Distinct From Other MPAL Subtypes,” International Journal of Laboratory Hematology 45, no. 2 (2023): 170–178.
- 15M. J. Oberley, S. Li, E. Orgel, C. Phei Wee, A. Hagiya, and M. R. G. O'Gorman, “Clinical Significance of Isolated Myeloperoxidase Expression in Pediatric B-Lymphoblastic Leukemia,” American Journal of Clinical Pathology 147, no. 4 (2017): 374–381.
- 16E. McGinnis, D. Yang, N. Au, et al., “Clinical and Laboratory Features Associated With Myeloperoxidase Expression in Pediatric B-Lymphoblastic Leukemia,” Cytometry Part B, Clinical Cytometry 100, no. 4 (2021): 446–453.
- 17S. S. Raikar, S. I. Park, T. Leong, et al., “Isolated Myeloperoxidase Expression in Pediatric B/Myeloid Mixed Phenotype Acute Leukemia Is Linked With Better Survival,” Blood 131, no. 5 (2018): 573–577.
- 18J. J. Huang, J. S. Appelbaum, K. Russell, et al., “Treatment Outcomes for Adults With Mixed Phenotypic Acute Leukemia: A Large Single-Center Retrospective Study,” Blood 142, no. S1 (2023): 2838–2838.
10.1182/blood-2023-188461 Google Scholar
- 19O. Hrusak, V. de Haas, J. Stancikova, et al., “International Cooperative Study Identifies Treatment Strategy in Childhood Ambiguous Lineage Leukemia,” Blood 132, no. 3 (2018): 264–276.
- 20E. Orgel, T. B. Alexander, B. L. Wood, et al., “Mixed-Phenotype Acute Leukemia: A Cohort and Consensus Research Strategy From the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force,” Cancer 126, no. 3 (2020): 593–601.
- 21C. Hurtz, G. B. Wertheim, J. P. Loftus, et al., “Oncogene-Independent BCR-Like Signaling Adaptation Confers Drug Resistance in Ph-Like ALL,” Journal of Clinical Investigation 130, no. 7 (2020): 3637–3653.
- 22T. H. Tran and S. K. Tasian, “Clinical Screening for Ph-Like ALL and the Developing Role of TKIs,” Hematology American Society of Hematology Education Program 2022, no. 1 (2022): 594–602.
